摘要:
Conjugates of formula I, below, are useful in biomedicinal applications such as delivery of drugs or labeling moieties or as components of liposomes or micelles. In formula I, A is a hydrophilic polymer, each of L and L′ is independently a linker group, B is a lipid moiety; and Z is a diagnostic ligand, a biologically relevant ligand, or a reactive linking moiety, which is generally linked to the phosphorus atom of the conjugate via a nitrogen, oxygen or sulfur atom in Z.
摘要:
A composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from a drug-resistant cancer is described. The composition is composed of a carrier molecule and a folate targeting ligand, which is covalently attached to the carrier, and the therapeutic compound. In one preferred embodiment, the carrier is a liposome having a surface coating of hydrophilic polymer chains where a folate ligand is attached to the free distal end of at least a portion of the hydrophilic polymer chains, and the therapeutic agent is entrapped in the liposomes. The composition is effective to achieve accumulation of the therapeutic compound in the cell in an amount sufficient to be cytotoxic. Also described are methods for administering a therapeutic compound to a person suffering from a multi-drug resistant condition.
摘要:
Polymer-biomolecule conjugates are prepared, generally in a site-specific or -selective manner, by a four-component condensation reaction. The method may be used to prepare conjugates having two polymer molecules attached at a single site on a biomolecule. The conjugates are typically water soluble and have beneficial pharmacological properties, such as reduced immunogenicity and increased circulation time.
摘要:
Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.
摘要:
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
摘要:
A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.
摘要:
A liposome composition for treating a bacterial infection is described. The composition includes liposomes having a surface coating of hydrophilic polymer chains and an entrapped drug-conjugate composed of ciprofloxacin conjugated to an amino acid.
摘要:
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
摘要:
A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.
摘要:
A method for conjugation of PEG to a protein in an aqueous solution at a pH less than or equal to about 7.0 or neutral pH comprising combining an activated PEG reagent and a protein in the presence of an activating agent at a pH of less than about 7.0 or neutral pH. In one embodiment, the method produces mixed populations of moderately PEGylated proteins, including 1:1, 2:1, and 3:1 PEGylated proteins.